Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Experimental and Applied Biomedical Research (EABR)
Volume 22 (2021): Issue 2 (June 2021)
Open Access
Olanzapine - Focus on the Cardiometabolic Side Effects
Miroslav Mitrovic
Miroslav Mitrovic
,
Tamara Nikolic
Tamara Nikolic
,
Marko Turnic
Marko Turnic
and
Dusan Djuric
Dusan Djuric
| Aug 05, 2021
Experimental and Applied Biomedical Research (EABR)
Volume 22 (2021): Issue 2 (June 2021)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Aug 05, 2021
Page range:
167 - 174
Received:
Aug 29, 2017
Accepted:
Sep 04, 2017
DOI:
https://doi.org/10.1515/sjecr-2017-0054
Keywords
olanzapine
,
weight gain
,
dyslipidemia
,
cardiovascular disease
© 2021 Miroslav Mitrovic et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Miroslav Mitrovic
Pharmanova doo Beograd
Serbia
Tamara Nikolic
University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy
Kragujevac, Serbia
Marko Turnic
Serbia
Dusan Djuric
University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy
Kragujevac, Serbia